鼻咽癌诱导-同期放化疗期间血浆EBV DNA时间清除模式用于风险分层
该研究回顾性分析2203例非转移性鼻咽癌患者诱导-同期放化疗期间三个时间点的血浆EBV DNA清除模式,识别出五种轨迹类型,其中诱导化疗后清除型5年无进展生存优于放疗后清除型、持续阳性型和复燃型,EBV DNA复燃偶见(3.3%)。
要点
- 诱导化疗后EBV DNA清除(D-U-U)患者5年PFS为82.9%,优于放疗后清除(75.9%)、持续阳性(52.5%)和复燃型(72.5%)。
- 持续阳性型(D-D-D)占11.7%,5年PFS仅52.5%,为高风险群体。
- EBV DNA复燃发生率3.3%,所有D-U-D模式患者确诊时均为III-IV期。
核心结论
- 诱导-同期放化疗期间EBV DNA时间清除模式可提供预后信息,识别高风险鼻咽癌患者并辅助个体化治疗策略。
- EBV DNA复燃偶见(3.3%),对诱导化疗后EBV DNA转阴的局部区域晚期患者考虑降低强度治疗时需谨慎。
研究设计与样本
- 回顾性分析新诊断非转移性鼻咽癌患者在诱导-同期放化疗期间的EBV DNA清除模式。
- EBV DNA在基线(T0)、诱导化疗结束(T1)和放疗结束(T2)三个时间点检测,记录为可检测(D)和不可检测(U)。
- 共纳入2203例鼻咽癌患者,分析EBV DNA模式与无进展生存的关联。
- 中位随访53.5个月(IQR,43.1-66.9)。
主要发现
- 识别出五种EBV DNA轨迹模式:I型(阴性稳定,U-U-U,7.3%)、II型(诱导化疗清除,D-U-U,42.8%)、III型(放疗清除,D-D-U,35.0%)、IV型(持续阳性,D-D-D,11.7%)、V型(复燃,D-U-D 1.5%、U-D-U 1.2%、U-D-D 0.4%、U-U-D 0.2%)。
- II型患者5年无进展生存率为82.9%(95% CI,80.4%-85.5%),优于III型的75.9%(72.8%-79.1%,P < .001)、IV型的52.5%(46.4%-59.5%,P < .001)和V型的72.5%(62.2%-84.6%,P = .028)。
- V型患者中D-U-D、U-D-U、U-D-D和U-U-D模式的5年无进展生存率分别为62.4%(46.2%-84.3%)、78.6%(63.1%-97.8%)、85.7%(63.3%-100.0%)和75.0%(42.6%-100.0%)。
- 所有33例D-U-D模式患者确诊时均为III-IV期疾病。
关键数值与推荐
- II型(D-U-U)5年PFS 82.9%(95% CI,80.4%-85.5%) vs III型(D-D-U)75.9%(72.8%-79.1%),P < .001。
- II型(D-U-U)5年PFS 82.9%(95% CI,80.4%-85.5%) vs IV型(D-D-D)52.5%(46.4%-59.5%),P < .001。
- II型(D-U-U)5年PFS 82.9%(95% CI,80.4%-85.5%) vs V型(复燃)72.5%(62.2%-84.6%),P = .028。
- V型中D-U-D模式5年PFS 62.4%(95% CI,46.2%-84.3%),U-D-U模式78.6%(63.1%-97.8%),U-D-D模式85.7%(63.3%-100.0%),U-U-D模式75.0%(42.6%-100.0%)。
临床怎么用
- 在诱导-同期放化疗期间按T0、T1、T2三个时间点检测血浆EBV DNA并记录清除模式,可用于识别高风险鼻咽癌患者。
- 对诱导化疗后EBV DNA转阴的局部区域晚期患者,考虑降低强度治疗时需谨慎。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Plasma Epstein-Barr virus (EBV) DNA is a widely used biomarker for nasopharyngeal carcinoma (NPC). Prior investigations predominantly assessed EBV DNA at a single time point, thus neglecting the differential prognostic implications of the temporal clearance pattern of EBV DNA during induction-concurrent (chemo)radiation therapy (RT). METHODS AND MATERIALS: We retrospectively reviewed EBV DNA clearance patterns during induction-concurrent chemoRT in newly diagnosed patients with nonmetastatic NPC. EBV DNA was tested at 3 time points (baseline [T0], end of induction chemotherapy [T1], and end of RT [T2]) and recorded as detectable (D) and undetectable (U). The association between EBV DNA pattern and progression-free survival was analyzed. RESULTS: A total of 2203 NPCs were included. Five distinct EBV DNA trajectory patterns were identified: type Ⅰ (negative-stable, U-U-U, 7.3%), type Ⅱ (induction chemotherapy-elimination, D-U-U, 42.8%), type Ⅲ (RT-elimination, D-D-U, 35.0%), type Ⅳ (persistent-positive, D-D-D, 11.7%), and type Ⅴ (resurgence, D-U-D [1.5%], U-D-U [1.2%], U-D-D [0.4%], or U-U-D [0.2%]). The median follow-up was 53.5 months (IQR, 43.1-66.9). Type Ⅱ patients displayed superior 5-year progression-free survival (82.9% [95% CI, 80.4%-85.5%]) versus type Ⅲ (75.9% [72.8%-79.1%], P < .001), type Ⅳ (52.5% [46.4%-59.5%], P < .001), and type Ⅴ (72.5% [62.2%-84.6%], P = .028). The 5-year progression-free survival for type V patients with "D-U-D," "U-D-U," "U-D-D," and "U-U-D" patterns was 62.4% (46.2%-84.3%), 78.6% (63.1%-97.8%), 85.7% (63.3%-100.0%), and 75.0% (42.6%-100.0%), respectively. All 33 patients with the "D-U-D" pattern had stage Ⅲ-Ⅳ disease at diagnosis. CONCLUSIONS: Temporal EBV DNA clearance patterns during induction-concurrent chemoRT provide valuable prognostic insights, enabling the identification of patients with high-risk NPC and informing personalized treatment strategies. Resurgence of EBV DNA may occur occasionally (3.3%). Caution is required when considering reduced-intensity therapy in patients with locoeregionally advanced disease when EBV DNA becomes U after induction chemotherapy.
引用
- Huang Z, Li Y, Wu W, et al. Plasma Epstein-Barr Virus DNA Temporal Clearance Pattern During Induction-Concurrent (Chemo)Radiation Therapy for Risk Stratification in Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2025. PMID: 40204246. doi:10.1016/j.ijrobp.2025.03.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。